Normal
[URL unfurl="true"]https://themarketherald.com.au/immutep-asximm-enters-second-collaboration-with-pfizer-and-merck-kgaa-for-insight-study-2022-11-29/[/URL]Immutep (IMM) has signed an agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a phase one clinical study in patients with urothelial cancer.The INSIGHT-005 trial will take place in Germany and will evaluate the safety and efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti), in combination with avelumab (BAVENCIO) in up to 30 patients with metastatic urothelial cancer.Live price chart: https://uk.advfn.com/p.php?pid=staticchart&s=ASX^IMM&p=5&t=1
[URL unfurl="true"]https://themarketherald.com.au/immutep-asximm-enters-second-collaboration-with-pfizer-and-merck-kgaa-for-insight-study-2022-11-29/[/URL]
Immutep (IMM) has signed an agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a phase one clinical study in patients with urothelial cancer.
The INSIGHT-005 trial will take place in Germany and will evaluate the safety and efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti), in combination with avelumab (BAVENCIO) in up to 30 patients with metastatic urothelial cancer.
Live price chart: https://uk.advfn.com/p.php?pid=staticchart&s=ASX^IMM&p=5&t=1
Hello and welcome to Aussie Stock Forums!
To gain full access you must register. Registration is free and takes only a few seconds to complete.
Already a member? Log in here.
